Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0000950170-24-089407
Filing Date
2024-08-01
Accepted
2024-08-01 17:03:56
Documents
7
Period of Report
2024-08-01

Document Format Files

Seq Description Document Type Size
1 6-K sndl-6-k-2024_q2.htm 6-K 19572
2 FS sndl-ex99_1.htm EX-99.1 2158138
3 MD&A sndl-ex99_2.htm EX-99.2 1179335
4 CEO sndl-ex99_3.htm EX-99.3 22687
5 CFO sndl-ex99_4.htm EX-99.4 22912
6 GRAPHIC img260723042_0.jpg GRAPHIC 4488
7 GRAPHIC img261646563_0.jpg GRAPHIC 4488
  Complete submission text file 0000950170-24-089407.txt   3416447
Mailing Address 919 11 AVENUE SW SUITE 300 CALGARY A0 T2R1P3
Business Address 919 11 AVENUE SW SUITE 300 CALGARY A0 T2R1P3 14039485227
SNDL Inc. (Filer) CIK: 0001766600 (see all company filings)

EIN.: 000000000 | State of Incorp.: A0 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39005 | Film No.: 241167711
SIC: 2833 Medicinal Chemicals & Botanical Products
(CF Office: 03 Life Sciences)